What is he best known for?
The fields of study he is best known for:
- Immune system
- Cancer
- Cytokine
Lionel Apetoh mainly investigates Immune system, Cancer research, Immunology, Immunogenic cell death and Cancer cell.
Lionel Apetoh works in the field of Immune system, focusing on Immunogenicity in particular.
His Cancer research study incorporates themes from Inflammasome, Antibiotics, Chemotherapy, CD8 and Adoptive cell transfer.
His Immunology research is multidisciplinary, incorporating perspectives in Cancer, Cytotoxic T cell, Cyclophosphamide and Myeloid-derived Suppressor Cell.
Lionel Apetoh works mostly in the field of Immunogenic cell death, limiting it down to topics relating to Antigen and, in certain cases, Radiation therapy, as a part of the same area of interest.
His work deals with themes such as Cell, Innate immune system and Cell biology, which intersect with Cancer cell.
His most cited work include:
- Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. (2103 citations)
- Calreticulin exposure dictates the immunogenicity of cancer cell death (1856 citations)
- Calreticulin exposure dictates the immunogenicity of cancer cell death (1856 citations)
What are the main themes of his work throughout his whole career to date?
Lionel Apetoh mainly focuses on Immune system, Immunology, Cancer research, Cancer and Cell biology.
The Immune system study combines topics in areas such as Cancer cell and Cytotoxic T cell.
His study focuses on the intersection of Immunology and fields such as Chemotherapy with connections in the field of Oncology, Breast cancer, Immune checkpoint inhibitors and Tumor cells.
His research in Cancer research intersects with topics in Immune checkpoint, Inflammasome, Dendritic cell and Radiation therapy.
His work in the fields of Cell biology, such as STAT3, intersects with other areas such as Calreticulin.
As a part of the same scientific study, he usually deals with the Immunogenic cell death, concentrating on Cisplatin and frequently concerns with Oxaliplatin.
He most often published in these fields:
- Immune system (128.48%)
- Immunology (91.77%)
- Cancer research (70.89%)
What were the highlights of his more recent work (between 2017-2021)?
- Cancer research (70.89%)
- Immune system (128.48%)
- Cancer (55.70%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Cancer research, Immune system, Cancer, T cell and Cell biology.
His Cancer research research integrates issues from Cancer cell, Inflammation, Secretion and Immune checkpoint.
His Immune system study combines topics from a wide range of disciplines, such as Autophagy and Radiation therapy.
His Cancer research incorporates themes from Microbiome and Chemotherapy.
His T cell research includes elements of Acquired immune system, Cell and Innate immune system.
His Cell biology study combines topics in areas such as Apoptosis and THP1 cell line.
Between 2017 and 2021, his most popular works were:
- Crizotinib-induced immunogenic cell death in non-small cell lung cancer (68 citations)
- STING-dependent sensing of self-DNA drives silica-induced lung inflammation (59 citations)
- Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) (38 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Cancer
- Cytokine
His primary areas of investigation include Cell biology, Immunotherapy, Autophagy, Immune system and Innate immune system.
Lionel Apetoh has included themes like THP1 cell line, Activator and CARD domain in his Cell biology study.
His Immunotherapy research is multidisciplinary, relying on both Cancer cell, Lung cancer and Cisplatin.
Lionel Apetoh interconnects Computational biology and Programmed cell death in the investigation of issues within Autophagy.
Much of his study explores Immune system relationship to Cell.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
